No binding was observed in any control experiments, thus, sHLA-DRα2 binds specifically to CD4+ and CD8+ T cells leading to apoptosis in both subsets.
Similarly, [125I]CGRP binding was observed in the molecular layer of human cerebellum.
No significant binding was observed in PC-3 cells (negative control).
In dams, decreased D2 (24.6%) and D3 (36.9%) binding was observed in striatum.
Higher compound protein binding was observed in the brain than in the plasma.
High non-specific [ 18 F]flutemetamol binding was observed in the cerebral and cerebellar white matter in all evaluated TG and WT mice (Figure 5a).
Robust specific binding was observed in all four brain regions tested with cortex showing the highest specific binding with a specific/non-specific binding ratio of ~18.
When excess cold exendin-3 was added with [18F]exendin-4, no [18F]exendin-4 binding was observed in human pancreatic islet tissue sections (Fig. 8c d).
However, distractor response binding was observed in effector-change trials if participants were keeping the prime-action plan active during probe response execution.
Absence of 125I-Cry2Ab binding was observed in resistant insects (Fig. 1B, lane 3).
In addition, reduced binding was observed in comparison to the wildtype when GST-PBD-mutant was used.
